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Tabulated below are “targeted” or novel agents that arebeing or have been evaluated in non-small cell lung
cancer (NSCLC) and small cell lung cancer. Only compounds
that have entered clinical trials have been listed. The com-
pounds are listed by class, and under each class, they are
listed in the order of their phase of clinical development, with
those in the latest phase being listed first. The phase of
development in lung cancer is also noted if it differs from the
latest phase of development in other malignancies. The
classes are listed alphabetically, except for the first two
categories (epidermal growth factor receptor and vascular
endothelial growth factor receptor inhibitors) because drugs
from this category are approved for NSCLC and are in
common clinical practice. Drugs that do not fall into specific
broad categories are clumped under “others” at the end of the
Table 1. We have made every attempt to be current and
comprehensive, and this table is essentially designed to be
a quick reference tool; however, the information listed is
dynamic and constantly evolving, and therefore, the reader
is encouraged to look for further updates that may have
been reported after the publication of this table. This is
especially pertinent for compounds currently undergoing phase
III testing.
In the last column, the list of toxicities is given. This list
is not intended to be comprehensive, but only the prototypic
or most commonly seen “class effect” toxicities are noted.
The toxicity column has been left blank for compounds very
early in development for which mature toxicity data are not
available. The phase of the trial is also listed in the last but
one column. If the phase of development in lung cancer
differs from the overall development of the agent, then this
has been explicitly stated. Compounds still in phase I devel-
opment has been also listed. Nevertheless, only those com-
pounds of potential utility for lung cancer and that are also
enrolling patients with lung cancer are listed. If a compound
is undergoing lung cancer-specific phase I testing, then this
has also been stated.
When available, the generic name, trade name(s),
and other accepted name(s) or phrase(s) used to refer an
agent have also been listed. A blank space indicates that a
generic or trade name did not exist at the time of writing.
Nevertheless, this might have changed by the time this
article is published.
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